Se­ri­ous side ef­fects side­line small Roche study of an ex­per­i­men­tal Hunt­ing­ton’s drug from Io­n­is

Two years af­ter in-li­cens­ing an ex­per­i­men­tal an­ti­sense drug for Hunt­ing­ton’s dis­ease from Io­n­is, Roche in­ves­ti­ga­tors have been forced to halt a small ear­ly-stage study in the wake of a pair of se­ri­ous side ef­fects.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER